STOCKHOLM, SWEDEN--(Marketwire - January 10, 2012) -
Sobi President and CEO Geoffrey McDonough today made a company presentation at the J.P. Morgan Annual Healthcare Conference in San Francisco.
In his presentation Dr McDonough highlighted the newly implemented operational structure to focus on growth in three business lines: Core Products including Kineret® and Orfadin®, Specialty Distribution Portfolio focused mainly in the Nordic, Baltic, and CEE regions, and manufacturing for Refacto AF® in partnership with Pfizer. He emphasized the company’s overall goals to improve gross margin and cash flow, and to successfully commercialize the company’s three late stage projects. The late stage projects include Kiobrina®, an enzyme replacement therapy to improve growth in preterm infants, and long-acting recombinant coagulation factors 8 and 9 for hemophilia A and B being developed in collaboration with Biogen Idec.
Dr McDonough also commented on the new distribution agreement with the Italian company Gentium regarding Defibrotide in the Nordic and Baltic regions announced yesterday by Gentium. Defibrotide has the potential to become the first drug approved for the prevention and treatment of hepatic veno-occlusive disease (VOD) a serious and potentially fatal complication of hematopoietic stem- cell transplantation (HSCT).
An audiocast of the presentation is available at www.sobi.com.
Swedish Orphan Biovitrum (Sobi) Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the health of rare disease patients and their families. The product portfolio comprises about 60 marketed products as well as projects in the late clinical phase. Key therapeutic areas are Inflammation and Genetics & Metabolism. In 2010 Sobi had revenues of SEK 1.9 billion and around 500 employees. The share (STO: SOBI) is listed on OMX NASDAQ Stockholm. More information is available atwww.sobi.com.
JPM Press Release in pdf format: http://hugin.info/134557/R/1576550/491363.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
[HUG#1576550]
For further information, please contact:
Asa Stenqvist
Head of Communications and Investor Relations
Tel.: +46 8 697 21 88
